BMRN Relative Valuation
BMRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BMRN is overvalued; if below, it's undervalued.
Historical Valuation
BioMarin Pharmaceutical Inc (BMRN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 11.22 is considered Undervalued compared with the five-year average of 40.54. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 80.67 to 271.37 according to relative valuation methord. Compared to the current price of 53.82 USD , BioMarin Pharmaceutical Inc is Undervalued By 33.29%.
Relative Value
Fair Zone
80.67-271.37
Current Price：53.82
33.29%
Undervalued
11.22
PE
1Y
3Y
5Y
Trailing
Forward
9.88
EV/EBITDA
BioMarin Pharmaceutical Inc. (BMRN) has a current EV/EBITDA of 9.88. The 5-year average EV/EBITDA is 70.97. The thresholds are as follows: Strongly Undervalued below -172.20, Undervalued between -172.20 and -50.61, Fairly Valued between 192.56 and -50.61, Overvalued between 192.56 and 314.15, and Strongly Overvalued above 314.15. The current Forward EV/EBITDA of 9.88 falls within the Historic Trend Line -Fairly Valued range.
10.56
EV/EBIT
BioMarin Pharmaceutical Inc. (BMRN) has a current EV/EBIT of 10.56. The 5-year average EV/EBIT is 5.37. The thresholds are as follows: Strongly Undervalued below -191.92, Undervalued between -191.92 and -93.28, Fairly Valued between 104.01 and -93.28, Overvalued between 104.01 and 202.66, and Strongly Overvalued above 202.66. The current Forward EV/EBIT of 10.56 falls within the Historic Trend Line -Fairly Valued range.
3.12
PS
BioMarin Pharmaceutical Inc. (BMRN) has a current PS of 3.12. The 5-year average PS is 6.24. The thresholds are as follows: Strongly Undervalued below 2.98, Undervalued between 2.98 and 4.61, Fairly Valued between 7.87 and 4.61, Overvalued between 7.87 and 9.50, and Strongly Overvalued above 9.50. The current Forward PS of 3.12 falls within the Undervalued range.
11.24
P/OCF
BioMarin Pharmaceutical Inc. (BMRN) has a current P/OCF of 11.24. The 5-year average P/OCF is 36.93. The thresholds are as follows: Strongly Undervalued below -37.10, Undervalued between -37.10 and -0.08, Fairly Valued between 73.95 and -0.08, Overvalued between 73.95 and 110.97, and Strongly Overvalued above 110.97. The current Forward P/OCF of 11.24 falls within the Historic Trend Line -Fairly Valued range.
12.41
P/FCF
BioMarin Pharmaceutical Inc. (BMRN) has a current P/FCF of 12.41. The 5-year average P/FCF is 34.81. The thresholds are as follows: Strongly Undervalued below 5.68, Undervalued between 5.68 and 20.24, Fairly Valued between 49.37 and 20.24, Overvalued between 49.37 and 63.93, and Strongly Overvalued above 63.93. The current Forward P/FCF of 12.41 falls within the Undervalued range.
BioMarin Pharmaceutical Inc (BMRN) has a current Price-to-Book (P/B) ratio of 1.71. Compared to its 3-year average P/B ratio of 2.95 , the current P/B ratio is approximately -42.14% higher. Relative to its 5-year average P/B ratio of 3.19, the current P/B ratio is about -46.47% higher. BioMarin Pharmaceutical Inc (BMRN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 2.22%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 1.58% , the current FCF yield is about -100.00% lower.
1.71
P/B
Median3y
2.95
Median5y
3.19
7.98
FCF Yield
Median3y
2.22
Median5y
1.58
Competitors Valuation Multiple
The average P/S ratio for BMRN's competitors is , providing a benchmark for relative valuation. BioMarin Pharmaceutical Inc Corp (BMRN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 4.08%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BMRN decreased by 18.12% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 9.76 to 20.08.
The secondary factor is the Revenue Growth, contributed 4.08%to the performance.
Overall, the performance of BMRN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is BioMarin Pharmaceutical Inc (BMRN) currently overvalued or undervalued?
What is BioMarin Pharmaceutical Inc (BMRN) fair value?
How does BMRN's valuation metrics compare to the industry average?
What is the current P/B ratio for BioMarin Pharmaceutical Inc (BMRN) as of Dec 05 2025?
What is the current FCF Yield for BioMarin Pharmaceutical Inc (BMRN) as of Dec 05 2025?
What is the current Forward P/E ratio for BioMarin Pharmaceutical Inc (BMRN) as of Dec 05 2025?